SCHEMBL6357017

SCHEMBL6357017

N#Cc1ccc(NC(=O)c2cccc(Cl)c2)c(C(=O)O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.64
▸ KMT2A Q03164 3/20 0.64
▸ CYP1A2 P05177 1/20 0.64
▸ CYP3A4 P08684 1/20 0.64
▸ CYP2D6 P10635 1/20 0.64
▸ CYP2C9 P11712 1/20 0.64
▸ CYP2C19 P33261 1/20 0.64
▸ AKR1C4 P17516 2/20 0.63
▸ AKR1C3 P42330 2/20 0.63
▸ AKR1C2 P52895 2/20 0.63
▸ AKR1C1 Q04828 2/20 0.63
▸ SERPINE1 P05121 8/20 0.60
▸ CA12 O43570 1/20 0.55
▸ CA1 P00915 1/20 0.55
▸ CA2 P00918 1/20 0.55
▸ CA7 P43166 1/20 0.55
▸ CA9 Q16790 1/20 0.55
▸ GFER P55789 1/20 0.53
▸ PKM P14618 1/20 0.51
▸ KCNMA1 Q12791 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6351469 0.87 AKR1C2 (0.66) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL6353963 0.87 KMT2A (0.62) MEN1KMT2AAKR1C4AKR1C3AKR1C2
SCHEMBL19554161 0.85 CA2 (0.56) MEN1KMT2AAKR1C4AKR1C3AKR1C2
SCHEMBL6357568 0.85 ALDH1A1 (0.70) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL6359203 0.85 KMT2A (0.58) MEN1KMT2AAKR1C4AKR1C3AKR1C2
SCHEMBL6359497 0.85 KMT2A (0.53) MEN1KMT2AAKR1C4AKR1C3AKR1C2
SCHEMBL6819989 0.83 ALB (0.54) MEN1KMT2AAKR1C4AKR1C3AKR1C2
SCHEMBL6357140 0.83 MEN1 (0.60) MEN1KMT2AAKR1C4AKR1C3AKR1C2
SCHEMBL6349507 0.83 MEN1 (0.57) MEN1KMT2AAKR1C2AKR1C1SERPINE1
SCHEMBL6353195 0.83 KMT2A (0.52) MEN1KMT2AAKR1C4AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113450-A1 Antibacterial agents PHARMACIA & UPJOHN COMPANY 2005-05-26 — — US claimed
WO-2004018414-A2 ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113450-A1 Antibacterial agents CLPP, SPOUT1, SAMHD1 MEN1 3274/4885KMT2A 3645/4885CYP1A2 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback